CEL-SCI Corp CVM

Healthcare Biotechnology

CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.

NYSEAM:CVM - Post by User

CEL-SCI Corp

Bullboard Posts

Post by tofurkeyon Sep 21, 2010 11:43am

403 Views

Post# 17473929

Acquisition Rumour

Rumour:

Shares of Cel-Sci Corporation (NYSE: CVM) are running sharply higher today, on rumors that the biotech company may be bought out by a larger pharmaceutical company. As of now, there is no definitive rumor on which company may acquired CVM. CVM has a roughly $130 million market cap, so it is cheap based on a market cap metric.

CEL-SCI Corporation is best known for its Multikine drug, which isunder development for the treatment of cancer and is cleared for a PhaseIII clinical trial in advanced primary head and neck cancer patients. Multikine is a patented immunotherapeutic agent consisting of amixture of naturally occurring cytokines, including interleukins,interferons, chemokines, and colony-stimulating factors.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale